Pet Drug Reports

Drugs by active ingredient

Drug · single active ingredient

Cephalexin: adverse event reports

All products with this active ingredient · 1 FDA-approved application in the Green Book

2,837reports naming this ingredient, 1999–20260.2% of all reports · about 105 a year
147reports, 12 months to March 2026134 in the 12 months before
39.3%classed serious, as reportedof 2,714 reports stating it
9.8%record death or euthanasia, as reported277 reports
93.7%of reports concern dogs0.3% of all dog reports

2,837 adverse event reports in FDA's database list a drug whose active ingredient is recorded as cephalexin. The earliest was received in April 1999, the latest in March 2026. The Green Book lists 1 FDA-approved application with this single active ingredient.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 147 reports named it, up 10% from 134 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 105 reports a year and 0.2% of all 1,357,245 reports (0.3% of all dog reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

The signs named most often are vomiting (26.8%), lethargy (15.4%) and emesis (13.1%). A report can list several signs, so shares add to more than 100%; 1,275 different terms appear across these reports.

93.7% of reports concern dogs. Not every report describes illness: 11.5% were filed wholly or partly as lack of expected effectiveness. Of reports that state seriousness, 39.3% were classed as serious, and 9.8% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog507 · peak 20
Apr 2021: 8May 2021: 7Jun 2021: 7Jul 2021: 16Aug 2021: 10Sep 2021: 8Oct 2021: 5Nov 2021: 8Dec 2021: 4Jan 2022: 8Feb 2022: 9Mar 2022: 5Apr 2022: 3May 2022: 10Jun 2022: 6Jul 2022: 5Aug 2022: 4Sep 2022: 3Oct 2022: 11Nov 2022: 3Dec 2022: 3Jan 2023: 8Feb 2023: 4Mar 2023: 7Apr 2023: 3May 2023: 4Jun 2023: 6Jul 2023: 4Aug 2023: 6Sep 2023: 7Oct 2023: 10Nov 2023: 4Dec 2023: 7Jan 2024: 13Feb 2024: 8Mar 2024: 5Apr 2024: 10May 2024: 7Jun 2024: 4Jul 2024: 12Aug 2024: 13Sep 2024: 20Oct 2024: 10Nov 2024: 12Dec 2024: 14Jan 2025: 6Feb 2025: 13Mar 2025: 6Apr 2025: 12May 2025: 19Jun 2025: 9Jul 2025: 15Aug 2025: 13Sep 2025: 13Oct 2025: 16Nov 2025: 12Dec 2025: 10Jan 2026: 13Feb 2026: 5Mar 2026: 42022202320242025
Cat12 · peak 2
Sep 2021: 1Oct 2022: 1Feb 2024: 2Jul 2024: 1Sep 2024: 1Oct 2024: 1Aug 2025: 1Sep 2025: 1Oct 2025: 1Nov 2025: 1Jan 2026: 12022202320242025
Horse0 · peak 1
2022202320242025
Other9 · peak 2
Apr 2021: 1Jun 2022: 1Apr 2023: 1Oct 2023: 1Oct 2024: 1Feb 2025: 2Mar 2025: 1Apr 2025: 12022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

01863711999: 219992001: 32002: 32003: 320032005: 22006: 32007: 220072008: 22009: 22010: 320102011: 372012: 3342013: 37120132014: 2382015: 2562016: 32220162017: 2482018: 1912019: 15220192020: 1152021: 952022: 7220222023: 722024: 1342025: 15220252026: 23

2026 covers reports received through March 2026 only.

Signs listed in reports

share of cephalexin reports listing the termall dog reports

  1. Vomiting26.8%760
  2. Lethargy[unusually tired or inactive]15.4%438
  3. Emesis[vomiting]13.1%371
  4. Diarrhoea[diarrhea]7.9%223
  5. Overdose[more than the labelled amount was given]7.7%219
  6. Other abnormal test result NOS[abnormal laboratory result, type not specified]7.4%210
  7. Accidental exposure[exposure that was not intended]7.2%205
  8. Lack of efficacy - NOS[the product did not have the expected effect]6.5%184
  9. Anorexia[not eating]6.2%177
  10. Death by euthanasia[the animal was euthanized]5.1%144
  11. Seizure NOS[seizure, type not specified]4.7%134
  12. Death4.2%120
  13. Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]4.2%119
  14. Behavioural disorder NOS[behaviour change, type not specified]3.7%105
  15. Ataxia[unsteady, uncoordinated movement]3.6%102
  16. Elevated serum alkaline phosphatase (SAP)[a liver and bone enzyme above the normal range]3.4%97
  17. Pruritus[itching]3.4%97
  18. Leucocytosis NOS[high white blood cell count]2.6%74
  19. Elevated blood urea nitrogen (BUN)[a kidney value above the normal range]2.5%70
  20. Panting2.4%68
  21. Tablets, Abnormal[a product quality report, not a sign in an animal]2.3%66
  22. Skin lesion NOS[NOS: not otherwise specified]2.3%64
  23. Fever2.2%63
  24. Elevated total bilirubin[bilirubin above the normal range]2.2%62
  25. Elevated liver enzymes[liver enzymes above the normal range]2.1%60
  26. Ineffective, atopy control[legacy FDA term: the product did not have the expected effect (atopy control)]2.1%59

Top 30 of 1,275 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal34.9%989
Recovered with Sequela2.6%74
Ongoing28.2%799
Died5%142
Euthanized4.9%138
Outcome Unknown21.4%607

What kind of report it was

Safety issue84.7%2,403
Lack of expected effectiveness5.4%154
Both safety and lack of expected effectiveness6%171
Manufacturing or product defect3.8%108
Other0%1

Coloured bar: reports naming cephalexin. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Dog93.7%2,658
Cat3.1%89
Human exposure0.1%3
Ferret0.1%2

Single-breed animals

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year9%254
1 to 3 years24.5%696
4 to 7 years30%851
8 to 11 years22.8%648
12 years and over9.2%262
Age not given4.4%126

Weight of the animal

Under 5 kg (11 lb)5.3%149
5 to 9.9 kg (11–22 lb)12.3%348
10 to 24.9 kg (22–55 lb)28%795
25 to 44.9 kg (55–99 lb)42.6%1,208
45 kg and over (99 lb+)6.6%186
Weight not given5.3%151

Route of administration stated in reports: oral (1,882), intravenous (2), topical (2), ophthalmic (1), other (1), parenteral (1).

In context

MeasureCephalexinAll dog reportsAll reports
Reports2,837985,6751,357,245
Share of that pool's reports naming this drug—0.3%0.2%
Classed serious, of reports stating it39.3%38.3%38.6%
Death or euthanasia recorded, per 1,000 reports97.65563.8
Filed as lack of expected effectiveness (wholly or partly)11.5%—23%
Top term, share of reportsVomiting 26.8%19.7%—

This set accounts for 100% of all reports naming cephalexin, so no separate ingredient column is shown. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

FDA-approved products containing cephalexin (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.

Only one approved application matches this ingredient set. FDA's records still do not say which product a report concerned: the same ingredients are also dispensed as compounded, foreign-labelled and unapproved products, and the ingredient field is completed by whoever submitted the report.

Trade nameActive ingredientsSponsorApproved forApplication
RilexineCephalexinVirbac AH, Inc.DogsNADA 141-326

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about cephalexin reports

How many adverse event reports has FDA received for cephalexin?

2,837 reports record a drug with cephalexin as its active ingredient in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 147 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The Green Book lists 1 approved application with this ingredient alone; the reference list on this page names them without any counts.

What signs are reported most often?

vomiting (26.8%), lethargy (15.4%), emesis (13.1%), diarrhoea (7.9%) and overdose (7.7%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

dog (93.7%), cat (3.1%) and human exposure (0.1%). Among single-breed animals the most frequent labels are Labrador Retriever, German Shepherd Dog, Golden Retriever and Pit Bull; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

147 reports in the 12 months to March 2026, up 10% from 134 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that cephalexin harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of cephalexin?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.